Novel asymmetrically engineered antibody Fc variant with superior FcγR binding affinity and specificity compared with afucosylated Fc variant
F Mimoto, T Igawa, T Kuramochi, H Katada, S Kadono… - MAbs, 2013 - Taylor & Francis
Fc engineering is a promising approach to enhance the antitumor efficacy of monoclonal
antibodies (mAbs) through antibody-dependent cell-mediated cytotoxicity (ADCC). Glyco …
antibodies (mAbs) through antibody-dependent cell-mediated cytotoxicity (ADCC). Glyco …
[引用][C] Novel asymmetrically engineered antibody Fc variant with superior FcγR binding affinity and specificity compared with afucosylated Fc variant
F Mimoto, T Igawa, T Kuramochi, H Katada, S Kadono… - mAbs, 2013 - cir.nii.ac.jp
Novel asymmetrically engineered antibody Fc variant with superior FcγR binding affinity and
specificity compared with afucosylated Fc variant | CiNii Research CiNii 国立情報学研究所 学術 …
specificity compared with afucosylated Fc variant | CiNii Research CiNii 国立情報学研究所 学術 …
Novel asymmetrically engineered antibody Fc variant with superior FcγR binding affinity and specificity compared with afucosylated Fc variant.
F Mimoto, T Igawa, T Kuramochi, H Katada, S Kadono… - Mabs, 2013 - europepmc.org
Fc engineering is a promising approach to enhance the antitumor efficacy of monoclonal
antibodies (mAbs) through antibody-dependent cell-mediated cytotoxicity (ADCC). Glyco …
antibodies (mAbs) through antibody-dependent cell-mediated cytotoxicity (ADCC). Glyco …
[HTML][HTML] Novel asymmetrically engineered antibody Fc variant with superior FcγR binding affinity and specificity compared with afucosylated Fc variant
F Mimoto, T Igawa, T Kuramochi, H Katada, S Kadono… - mAbs, 2013 - ncbi.nlm.nih.gov
Fc engineering is a promising approach to enhance the antitumor efficacy of monoclonal
antibodies (mAbs) through antibody-dependent cell-mediated cytotoxicity (ADCC). Glyco …
antibodies (mAbs) through antibody-dependent cell-mediated cytotoxicity (ADCC). Glyco …
[PDF][PDF] Novel asymmetrically engineered antibody Fc variant with superior FcγR binding affinity and specificity compared with afucosylated Fc variant
M Shida-Kawazoe, K Hattori - 2013 - Citeseer
Monoclonal antibodies (mAbs) have enormous potential as anticancer therapeutics. MAbs
promote elimination of tumor cells by Fab-dependent and Fc-dependent mechanisms, such …
promote elimination of tumor cells by Fab-dependent and Fc-dependent mechanisms, such …
Novel asymmetrically engineered antibody Fc variant with superior FcγR binding affinity and specificity compared with afucosylated Fc variant
F Mimoto, T Igawa, T Kuramochi, H Katada… - …, 2013 - pubmed.ncbi.nlm.nih.gov
Fc engineering is a promising approach to enhance the antitumor efficacy of monoclonal
antibodies (mAbs) through antibody-dependent cell-mediated cytotoxicity (ADCC). Glyco …
antibodies (mAbs) through antibody-dependent cell-mediated cytotoxicity (ADCC). Glyco …
Novel asymmetrically engineered antibody Fc variant with superior FcγR binding affinity and specificity compared with afucosylated Fc variant.
F Mimoto, T Igawa, T Kuramochi, H Katada, S Kadono… - Mabs, 2013 - europepmc.org
Fc engineering is a promising approach to enhance the antitumor efficacy of monoclonal
antibodies (mAbs) through antibody-dependent cell-mediated cytotoxicity (ADCC). Glyco …
antibodies (mAbs) through antibody-dependent cell-mediated cytotoxicity (ADCC). Glyco …